Zonisamide: A Comprehensive, Updated Review for the Clinician.

Autor:	Gidal BE; Pharmacy Practice & Translational Research (BEG), University of Wisconsin-Madison; Department of Neurology (TR), Nicklaus Children Hospital; Department of Neurology, Florida International University, Miami, FL; Department of Neurological Sciences (MCS), Rush Medical College; Rush University Medical Center, Chicago, IL; and Pediatric Neurology (JWW), University of Tennessee Health Science Center; Neuroscience Institute & Le Bonheur Comprehensive Epilepsy Program, Le Bonheur Children's Hospital, Memphis, TN., Resnick T; Pharmacy Practice & Translational Research (BEG), University of Wisconsin-Madison; Department of Neurology (TR), Nicklaus Children Hospital; Department of Neurology, Florida International University, Miami, FL; Department of Neurological Sciences (MCS), Rush Medical College; Rush University Medical Center, Chicago, IL; and Pediatric Neurology (JWW), University of Tennessee Health Science Center; Neuroscience Institute & Le Bonheur Comprehensive Epilepsy Program, Le Bonheur Children's Hospital, Memphis, TN., Smith MC; Pharmacy Practice & Translational Research (BEG), University of Wisconsin-Madison; Department of Neurology (TR), Nicklaus Children Hospital; Department of Neurology, Florida International University, Miami, FL; Department of Neurological Sciences (MCS), Rush Medical College; Rush University Medical Center, Chicago, IL; and Pediatric Neurology (JWW), University of Tennessee Health Science Center; Neuroscience Institute & Le Bonheur Comprehensive Epilepsy Program, Le Bonheur Children's Hospital, Memphis, TN., Wheless JW; Pharmacy Practice & Translational Research (BEG), University of Wisconsin-Madison; Department of Neurology (TR), Nicklaus Children Hospital; Department of Neurology, Florida International University, Miami, FL; Department of Neurological Sciences (MCS), Rush Medical College; Rush University Medical Center, Chicago, IL; and Pediatric Neurology (JWW), University of Tennessee Health Science Center; Neuroscience Institute & Le Bonheur Comprehensive Epilepsy Program, Le Bonheur Children's Hospital, Memphis, TN.
Jazyk:	angličtina
Zdroj:	Neurology. Clinical practice [Neurol Clin Pract] 2024 Feb; Vol. 14 (1), pp. e200210. Date of Electronic Publication: 2023 Nov 10.
DOI:	10.1212/CPJ.0000000000200210
Abstrakt:	Purpose of Review: Zonisamide (ZNS) was first approved in the United States in 2000 for the adjunctive treatment of patients aged 16 years or older with partial (focal) seizures. Although ZNS has been proven to treat multiple seizure types, it has been largely underutilized in US clinical practice. Recent Findings: Published literature demonstrated that antiseizure medications (ASMs) acting on Na + and Ca 2+ channels may add beneficial effects in many seizure types by reducing seizure frequency and leading to overall improvements. In addition, effects of ZNS may lead to clinical improvements in Parkinson disease, alcohol and sleep disorders, pain, and migraine. ZNS is available in multiple formulations and is a safe and effective, broad spectrum ASM. Summary: The purpose of this review was to provide an update to what is known about the efficacy of ZNS and where it shows benefits in the treatment of patients with epilepsy and other CNS disorders through its many unique mechanisms of action. Competing Interests: B.E. Gidal—Speaking honoraria: Azurity, Aquestive, SK Lifescience, Jazz. Consulting: UCB, SK-Lifescience, Jazz, Azurity, Eisai. M. Smith—Speaking: SK Lifescience, Neurelis. Consulting: Azurity, SK Lifescience, Neurelis. J. Wheless—LivNova, Eisai, Supernus, Envision, UCB, Neurelis, Xenon, Marinus, Biomarin, SK Lifescience; Consulting: Xenon, Marinus, Azurity. Grants: TSC Alliance, NIH, Supernus, Neuro Event Labs, Marinus, Neurelis, Epiwatch, SK Lifescience, Longboard, Biohaven, UCB, Shainberg Foundation. T. Resnick—Speaking: Sunovion, UCB, Eisai. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.TAKE-HOME POINTS→ ZNS's long half-life and once-daily dosing schedule contribute to improved adherence compared with other antiseizure medications (ASMs) with more frequent administration.→ ZNS is generally well-tolerated and has manageable safety issues. Its multiple mechanisms of action (MOAs) allow for coadministration with ASMs of different MOAs, increasing medication efficacy, and reducing seizure frequency.→ ZNS is a safe and effective ASM with therapeutic indications in multiple epilepsy etiologies and with potential benefits in other disease states. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu